Icotrokinra Shows High Efficacy and Safety in Treating Adolescent ...
Jun 25, 2025 · No new safety concerns emerged, supporting the drug’s efficacy and safety in both adolescents and adults. Icotrokinra is a first-in-class investigational targeted oral peptide that …
Icotrokinra results show potential to set a new standard of treatment …
Mar 8, 2025 · Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe …
Icotrokinra Clinical Study Results Demonstrate Its Potential
Mar 10, 2025 · Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor and is being studied in adults and adolescents 12 years of age and …
Background Icotrokinra for plaque psoriasis • Patients with moderate-to-severe plaque psoriasis (PsO) are generally limited to injectable therapies to achieve high-level eficacy with a …
Icotrokinra Shows Efficacy and Safety in Adolescents With …
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the interleukin (IL)-23 receptor and is being studied in adults and adolescents aged 12 and older …
Icotrokinra Improves Skin Clearance and Cuts Plaque Psoriasis …
Nov 19, 2024 · Icotrokinra is an investigational oral IL-23 inhibitor peptide. Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe …
Icotrokinra results show 75% of adolescents with plaque psoriasis ...
Apr 10, 2025 · ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults …
Icotrokinra Clinical Study Results Demonstrate Its Potential to …
Mar 8, 2025 · JNJ-77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients with Plaque Psoriasis: Results from the Phase …
Nov 14, 2024 · Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week …
J&J Posts Positive Icotrokinra Trial Results In Adolescents With Plaque …
Apr 10, 2025 · Drug major Johnson & Johnson (JNJ) on Tursday announced positive Icotrokinra results, which showed that 75% of adolescents with plaque psoriasis or PsO achieved …